- AU$320.19m
- AU$338.72m
- NZ$195.41m
- 94
- 41
- 63
- 72
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 16 | ||
| PEG Ratio (f) | 0.74 | ||
| EPS Growth (f) | 27.65% | ||
| Dividend Yield (f) | 0.8% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.96 | ||
| Price to Tang. Book | 10.14 | ||
| Price to Free Cashflow | 18 | ||
| Price to Sales | 1.78 | ||
| EV to EBITDA | 14.03 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 20.33% | ||
| Return on Equity | 19.38% | ||
| Operating Margin | 12.4% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | NZ$m | 105.6 | 113.11 | 130.31 | 156.64 | 195.41 | 223.57 | 258.68 | 18.08% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | +248.27 | +157.89 | -46.41 | +46.51 | +8.83 | +48.15 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AFT Pharmaceuticals Limited is a New Zealand-based multinational pharmaceutical company. The Company develops, markets and distributes a portfolio of pharmaceutical products across a range of therapeutic categories, which are distributed across three pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Its product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. The Company develops and in-licenses products for sale by its own dedicated sales teams in Australia and New Zealand and in certain Southeast Asian markets, and out-licenses its products to local licensees and distributors in the rest of the world. A-Scabies, Allersoothe, Allersoothe Elixir, BecloClear, Bites, Calci-Tab, Candacort, Candacort Minipak, Candaderm, Coco-Scalp, Combolieve, Cromo-Fresh, Dry skin, Eczema, Emulsifying Ointment BP, Fenpaed, Fenpaed Double Strength, Ferro-Sachets, HYLO-FORTE and others.
Directors
- David Flacks NEC
- Hartley Campbell Atkinson CEO
- Malcolm Dennis Tubby CFO
- Calvin Mackenzie GMG
- Marree Atkinson EDR
- Louise Clayton OTH
- Scott Crawford OTH
- Vladimir Ilievski OTH
- Murray Keith OTH
- Ioana Stanescu OTH
- Brendon Woodhead OTH
- Anita Baldauf NID
- Jon Lamb NID
- John Wilson NID
- Ted Witek NID
- Last Annual
- March 31st, 2024
- Last Interim
- March 31st, 2024
- Incorporated
- September 4th, 1997
- Public Since
- December 22nd, 2015
- No. of Shareholders
- 2,133
- No. of Employees
- 110
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 104,866,260
- Address
- Level 1, 129 Hurstmere Road, AUCKLAND, 0622
- Web
- http://www.aftpharm.com/
- Phone
- +64 94880232
- Auditors
- Deloitte
Upcoming Events for AFP
Similar to AFP
Acrux
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Anatara Lifesciences
Australian Stock Exchange - SEATS
Argent BioPharma
Australian Stock Exchange - SEATS
Biome Australia
Australian Stock Exchange - SEATS
FAQ
What is the AFT Pharmaceuticals share price?
As of Today at 19:34 UTC, shares in AFT Pharmaceuticals are trading at AU$2.91. This share price information is delayed by 15 minutes.
How has the AFT Pharmaceuticals share price performed this year?
Shares in AFT Pharmaceuticals last closed at AU$2.91 and the price had moved by -13.91% over the past 365 days. In terms of relative price strength the AFT Pharmaceuticals share price has underperformed the ASX All Ordinaries Index by -23.64% over the past year.
What are the analyst and broker recommendations for AFT Pharmaceuticals?
The overall consensus recommendation for AFT Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the AFT Pharmaceuticals dividend yield?
The AFT Pharmaceuticals dividend yield is 0.51% based on the trailing twelve month period.
Does AFT Pharmaceuticals pay a dividend?
Last year, AFT Pharmaceuticals paid a total dividend of NZ$0.02, and it currently has a trailing dividend yield of 0.51%. We do not have any data on when AFT Pharmaceuticals is to next pay dividends.
When does AFT Pharmaceuticals next pay dividends?
We do not have data on when AFT Pharmaceuticals is to next pay dividends. The historic dividend yield on AFT Pharmaceuticals shares is currently 0.51%.
How do I buy AFT Pharmaceuticals shares?
To buy shares in AFT Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of AFT Pharmaceuticals?
As of the previous close price of AU$2.91, shares in AFT Pharmaceuticals had a market capitalisation of AU$320.19m.
Where are AFT Pharmaceuticals shares listed?
Here are the trading details for AFT Pharmaceuticals:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: AFP
What kind of share is AFT Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum AFT Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a AFT Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in AFT Pharmaceuticals is AU$3.45. That is 18.55% above the last closing price of AU$2.91.
Analysts covering AFT Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of NZ$0.16 for the next financial year.
Find out moreWhat is the trend in the AFT Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AFT Pharmaceuticals. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -7.64%.
As of the last closing price of AU$2.91, shares in AFT Pharmaceuticals were trading -6.42% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the AFT Pharmaceuticals PE Ratio?
The AFT Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 16. The shares last closed at AU$2.91.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of AFT Pharmaceuticals?
AFT Pharmaceuticals' management team is headed by:
- David Flacks - NEC
- Hartley Campbell Atkinson - CEO
- Malcolm Dennis Tubby - CFO
- Calvin Mackenzie - GMG
- Marree Atkinson - EDR
- Louise Clayton - OTH
- Scott Crawford - OTH
- Vladimir Ilievski - OTH
- Murray Keith - OTH
- Ioana Stanescu - OTH
- Brendon Woodhead - OTH
- Anita Baldauf - NID
- Jon Lamb - NID
- John Wilson - NID
- Ted Witek - NID